Fannin Innovation Studio

Procyrion, Inc. is a clinical-stage medical device company based in Houston, Texas, specializing in the development of circulatory assist technologies. Founded in 2005, the company has created the Aortix Heart Pump, a non-surgical, catheter-deployed device designed for patients suffering from heart failure who cannot be adequately treated with medication alone. This innovative pump is implanted through a catheter inserted in the leg and is positioned between the heart and kidneys to alleviate the burden on the failing heart and improve organ perfusion. By addressing cardiorenal syndrome, Aortix aims to relieve symptoms of heart failure, particularly for patients who are diuretic resistant or in acute decompensation. The device's design allows it to be less invasive than traditional options, providing a critical solution for the significant number of adults over 40 who may face heart failure in their lifetime.

Allterum Therapeutics is a biopharmaceutical company focused on developing targeted treatments for relapsed acute lymphoblastic leukemia and other cancers characterized by IL-7 receptor expression. The company is advancing a monoclonal antibody, originally developed at the National Cancer Institutes, which is designed to specifically target and eliminate cancer cells while minimizing the side effects commonly associated with traditional chemotherapy. In addition to acute lymphoblastic leukemia, Allterum is also exploring the potential of this antibody for use in treating relapsed or refractory solid tumors with IL-7 receptor over-expression, aiming to provide effective therapeutic options for pediatric patients with complex cancer types.

Procyrion, Inc. is a clinical-stage medical device company based in Houston, Texas, specializing in the development of circulatory assist technologies. Founded in 2005, the company has created the Aortix Heart Pump, a non-surgical, catheter-deployed device designed for patients suffering from heart failure who cannot be adequately treated with medication alone. This innovative pump is implanted through a catheter inserted in the leg and is positioned between the heart and kidneys to alleviate the burden on the failing heart and improve organ perfusion. By addressing cardiorenal syndrome, Aortix aims to relieve symptoms of heart failure, particularly for patients who are diuretic resistant or in acute decompensation. The device's design allows it to be less invasive than traditional options, providing a critical solution for the significant number of adults over 40 who may face heart failure in their lifetime.

Pulmotect, Inc. is a biopharmaceutical company focused on developing inhaled therapeutics aimed at preventing and treating respiratory infections, particularly in cancer patients with compromised immune systems. Founded in 2007 and headquartered in Houston, Texas, the company offers PUL-042, a clinical stage inhaled therapeutic that rapidly stimulates the innate immune system, providing immediate and effective protection against a wide range of pathogens, including bacterial pneumonia, influenza, and fungal pneumonia, as well as threats from Class A bioterror agents such as anthrax and plague. By enhancing the body’s natural defenses, Pulmotect's products aim to significantly reduce morbidity and mortality associated with severe respiratory diseases.

Pulmotect, Inc. is a biopharmaceutical company focused on developing inhaled therapeutics aimed at preventing and treating respiratory infections, particularly in cancer patients with compromised immune systems. Founded in 2007 and headquartered in Houston, Texas, the company offers PUL-042, a clinical stage inhaled therapeutic that rapidly stimulates the innate immune system, providing immediate and effective protection against a wide range of pathogens, including bacterial pneumonia, influenza, and fungal pneumonia, as well as threats from Class A bioterror agents such as anthrax and plague. By enhancing the body’s natural defenses, Pulmotect's products aim to significantly reduce morbidity and mortality associated with severe respiratory diseases.

Procyrion, Inc. is a clinical-stage medical device company based in Houston, Texas, specializing in the development of circulatory assist technologies. Founded in 2005, the company has created the Aortix Heart Pump, a non-surgical, catheter-deployed device designed for patients suffering from heart failure who cannot be adequately treated with medication alone. This innovative pump is implanted through a catheter inserted in the leg and is positioned between the heart and kidneys to alleviate the burden on the failing heart and improve organ perfusion. By addressing cardiorenal syndrome, Aortix aims to relieve symptoms of heart failure, particularly for patients who are diuretic resistant or in acute decompensation. The device's design allows it to be less invasive than traditional options, providing a critical solution for the significant number of adults over 40 who may face heart failure in their lifetime.